The DOI matches its Crossref record; 195 of the 201 references it cites were found in a registry or an index.
Genes associated with Alzheimer's disease: an overview and current status
Open accessAbstract
Alzheimer's disease (AD) is a progressive, neurodegenerative disease and the most common form of dementia in elderly people. It is an emerging public health problem that poses a huge societal burden. Linkage analysis was the first milestone in unraveling the mutations in APP, PSEN1, and PSEN2 that cause early-onset AD, followed by the discovery of apolipoprotein E-ε4 allele as the only one genetic risk factor for late-onset AD. Genome-wide association studies have revolutionized genetic research and have identified over 20 genetic loci associated with late-onset AD. Recently, next-generation sequencing technologies have enabled the identification of rare disease variants, including unmasking small mutations with intermediate risk of AD in PLD3, TREM2, UNC5C, AKAP9, and ADAM10. This review provides an overview of the genetic basis of AD and the relationship between these risk genes and the neuropathologic features of AD. An understanding of genetic mechanisms underlying AD pathogenesis and the potentially implicated pathways will lead to the development of novel treatment for this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It takes 10–20 years for AD to manifest itself (e.g., [5, 69]).”
From Current therapeutics for Alzheimer’s disease and clinical trials (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Research works printed but not linked: 1
- [113]Rajagopalan P Hibar DP Thompson PM TREM2 and neurodegenerative disease N Engl J Med 2013 369 16 1565 1567 24131186 PMC4024453
Cited by
Sorted by citations
Items 301–311 of 311
Valverde, A. (2020) · theses.fr (ABES) · doi:10.70675/f1b70734zf4e3z4870z8fbdz950d831642a7
Exploration de nouveaux biomarqueurs plasmatiques pour le diagnostic de la maladie d’Alzheimer
Rossi, E. (2021) · theses.fr (ABES) · doi:10.70675/71230be4z1955z4fafzb1b8z8ff71a4edaff
Wang, Q., Fang, C.-L., Bao, T., & Niu, R.-Z. (2026) · Journal of Molecular Neuroscience · doi:10.1007/s12031-026-02519-8
Jose, R. P., Jayabal, J., Yagoo, A., Vilvest, J., & Vaishnika, A. M. (2026) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-026-00792-6
PathoAnalyzer-I: An Integrative Bioinformatics Platform for Chronic Disease Analysis
Aguerd, A., Bennis, F., & Chegdani, F. (2026) · Bioinformatics and Biology Insights · doi:10.1177/11779322261433663
Qin, X. H., Li, Q., Xu, X., Wu, Y., Zhu, Y., Wu, J., Fang, Y., Chen, Q., Wang, S.-H., Jiang, Y., et al. (2026) · Advanced Science · doi:10.1002/advs.75730 · Cited by 3
Current hypothesis for AD progression
Kim, C. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45844-6.00016-0
Molecular and genetic basis of alzheimer’s disease and emerging treatment Modalities
Varshney, H., & Siddique, Y. H. (2026) · Neurodegenerative Disease Management · doi:10.1080/17582024.2026.2739332
Metadata
- Authors
- Giri, M., Lü, Y., & Zhang, M.
- Affiliations
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Venue
- Clinical Interventions in Aging
- Publisher
- Informa UK Limited
- Published
- 2016-05
- Volume
- 11
- Pages
- 665
- ISSN
- 1176-9092 (ISSN-L)
- 1178-1998
- PMC
- PMC4876682
- OpenAlex
- W2405825843
- Cited by
- 311
- References
- 201
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 33 · 2023: 33 · 2022: 41 · 2021: 36 · 2020: 41 · 2019: 35 · 2018: 29 · 2017: 21 · 2016: 7
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Clinical Interventions in Aging (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, genetic risk factors, APP, presenilin 1, presenilin 2, APOE ε4, late-onset Alzheimer's disease, early-onset Alzheimer's disease, genome-wide association study, rare variants, PLD3, TREM2, UNC5C, AKAP9, ADAM10, neuropathology, pathogenesis
- MeSH terms
- Alzheimer Disease, Humans, Mutation, Risk Factors, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Apolipoprotein E4, Presenilin-1, Presenilin-2, Genome-Wide Association Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
